Aytu BioPharma, Inc (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 mi.
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
Aytu BioPharma, Inc : Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript February 14, 2024 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.25. Aytu BioPharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the […]